Modular evo

We reviewed the medical records and collected the laboratory data of all patients. First, the serum HBV DNA load was measured using a real-time polymerase chain reaction. Second, HBeAg and anti-HBe levels were determined using commercially available enzyme immunoassays (Alisei Quality System; RADIM, Rome, Italy). Third, serum HBsAg levels were quantitatively measured using Elecsys HBsAg II immunoassays (Roche Professional Diagnostics, Rotkreuz, Switzerland). Fourth, liver biochemistry, including serum ALT, AST, albumin, total bilirubin, and direct bilirubin levels were examined using the colorimetric method (MODULAR EVO; Hoffmann-La Roche Ltd., Basel, Switzerland). Finally, parameters of the haematopoietic function, including the white blood cell count, platelet count, lymphocyte count, and hemoglobin count, were recorded.

The liver tissue from the human subjects was examined by immunohistochemistry to evaluate the expression of SOCS family. Normal liver tissue sample was obtained from the tissue bank of West China Hospital, SCU. As mentioned before, the SOCS proteins would be stained brown as well. Samples with stained particles in the cytoplasm were defined as positive samples. The expression level of SOCS were also scored by the two pathologists mentioned before.
The serum samples collected at each medical assessment were detected for HBV-DNA quantification (Lightcycler-480, Roche, Switzerland), serum makers of HBV infection (Alisei Quality System, RADIM, Italy), liver and kidney function (Modular EVO, Roche, Switzerland) and prothrombin time (Sysmex CA-7000 Systems, Sysmex, Japan). The human subjects also received routine blood and urine examination and electrocardiogram. According to the therapeutic efficacy, those with complete or partial virological, serological or biochemical responses were assigned into the response group, while the rest were assigned into the non-response group.